{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T22:46:58Z","timestamp":1774565218624,"version":"3.50.1"},"reference-count":38,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":664,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2000,3]]},"abstract":"<jats:title>Abstract:<\/jats:title><jats:p><jats:italic>Background<\/jats:italic>: Although the primary treatment of symptomatic cytomegalovirus (CMV) disease in organ transplant recipients is successful in &gt;90% of individuals, relapsing disease, particularly in those with primary infection, remains an important problem. Previously, we had observed that the rate of symptomatic recurrence was &gt;60% in those with primary disease (seronegative for CMV prior to transplant), and approximately 20% in those who were seropositive prior to transplant. The present study was undertaken to determine whether a maintenance regimen of oral ganciclovir for 2\u20133 months added to the routine 14\u201321 days of intravenous ganciclovir would further prevent symptomatic CMV recurrence.<\/jats:p><jats:p><jats:italic>Methods<\/jats:italic>: From May 1995 until June 1998, all kidney and liver transplant recipients with confirmed tissue\u2010invasive CMV disease or CMV syndrome were treated with 14\u201321 days of intravenous ganciclovir (5 mg\/kg b.i.d. with dose adjusted for renal dysfunction) followed by 2\u20133 months of oral ganciclovir (2 g daily). The incidence of recurrence of CMV disease and\/or viremia during and after oral therapy was then determined over a mean follow\u2010up of 530.6 days.<\/jats:p><jats:p><jats:italic>Results<\/jats:italic>: Thirty\u2010seven patients, 19 kidney and 18 liver transplant recipients, were studied; 5 had biopsy\u2010proven tissue\u2010invasive disease (13.5) and 32 suffered a CMV syndrome (86.5). Twenty\u2010one of these patients (58.6) were seronegative for CMV prior to transplant and received an allograft from a seropositive donor (D+\/R\u2212). Overall, 10 patients (27.0) developed CMV recurrence. Eight of 21 patients who were D+\/R\u2212 for CMV (38.1) developed recurrence as opposed to 2 of 16 patients with other serologic status (12.5) (<jats:italic>P<\/jats:italic>=0.14). Patients with recurrent CMV disease and\/or viremia had a peak antigenemia assay titer during their initial CMV event of 319.2 positive cells\/2 slides compared with 109.8 positive cells\/2 slides for patients without recurrent CMV infection (<jats:italic>P<\/jats:italic>=0.14); the trend of having a higher peak antigenemia assay titer among patients who recurred occurred both in patients who were at risk of primary CMV infection (D+\/R\u2212 for CMV) and in those who were not. Two patients developed recurrent infection with strains of CMV that were resistant to ganciclovir.<\/jats:p><jats:p><jats:italic>Conclusions<\/jats:italic>: This new therapeutic regimen of oral ganciclovir following intravenous ganciclovir slightly reduced the overall rate of recurrent CMV disease and\/or viremia, but it still did not adequately prevent CMV recurrence in patients who are at risk of primary infection prior to transplant. Of particular concern, 2 patients with primary infection treated with this regimen developed ganciclovir\u2010resistant recurrent disease (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#fn1\">Note<\/jats:ext-link>).<\/jats:p>","DOI":"10.1034\/j.1399-3062.2000.020102.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T21:25:54Z","timestamp":1047504354000},"page":"2-10","source":"Crossref","is-referenced-by-count":27,"title":["Prevention dof recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir"],"prefix":"10.1111","volume":"2","author":[{"given":"N.","family":"Turgeon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Doran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Basgoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.E.","family":"Tolkoff\u2010Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.B.","family":"Cosimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.H.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-2490-8_24"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198007000-00004"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199605150-00001"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198807000-00015"},{"issue":"4","key":"e_1_2_6_6_2","first-page":"22","article-title":"Use of ganciclovir plus cytomegalovirus immune globulin to treat CMV pneumonia in orthotopic liver transplant recipients.","volume":"25","author":"George MJ","year":"1993","journal-title":"Transplant Proc"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1001\/jama.1987.03390220080025","article-title":"Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts.","volume":"257","author":"Erice A","year":"1987","journal-title":"J Am Med Assoc"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198808000-00008"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199101000-00015"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0022-5347(17)36918-5","article-title":"Therapeutic use of ganciclovir for invasive cytomegalovirus infection in cadaveric renal allograft recipients.","volume":"148","author":"Jordan ML","year":"1992","journal-title":"J Urol"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1989.01410120093018"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1993.01420140042007"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/139.4.465"},{"issue":"1","key":"e_1_2_6_14_2","first-page":"34","article-title":"Recurrent cytomegalovirus disease in solid\u2010organ transplant recipients.","volume":"27","author":"Falagas ME","year":"1995","journal-title":"Transplant Proc"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/514555"},{"key":"e_1_2_6_16_2","first-page":"1422","article-title":"Factors associated with recurrent cytomegalovirus disease after small bowel transplantation.","volume":"26","author":"Ma\u00f1ez R","year":"1994","journal-title":"Transplant Proc"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)05535-9"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(98)00283-8"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1399-0012.1994.tb00940.x","article-title":"Management of the renal allograft recipient: immunosuppressive protocols for long\u2010term success.","volume":"8","author":"Delmonico FL","year":"1994","journal-title":"Clin Transplant"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199901270-00010"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.Supplement_7.S839"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199304000-00030"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198710223171703"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199001000-00015"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90279-X"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-1-199507010-00002"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199812270-00036"},{"key":"e_1_2_6_28_2","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1128\/jcm.31.10.2824-2827.1993","article-title":"Cytomegalovirus antigenemia: clinical correlations in transplant recipients and in patients with AIDS.","volume":"31","author":"Mazzulli T","year":"1993","journal-title":"J Clin Microbiol"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-0934(90)90122-V"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856010-00012"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606063342302"},{"key":"e_1_2_6_32_2","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.1978.03290220058017","article-title":"Primary cytomegalovirus and opportunistic infections. Incidence in renal transplant recipients.","volume":"240","author":"Chatterjee SN","year":"1978","journal-title":"J Am Med Assoc"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.Supplement_7.S754"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806113382407"},{"key":"e_1_2_6_35_2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/00007890-199409000-00007","article-title":"Cytomegalovirus infection in transplant recipients: the role of tumor necrosis factor.","volume":"58","author":"Fietze E","year":"1994","journal-title":"Transplantation"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199705270-00031"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199702150-00026"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199808150-00008"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.11.1975"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-3062.2000.020102.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-3062.2000.020102.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1399-3062.2000.020102.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T10:25:22Z","timestamp":1733567122000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1399-3062.2000.020102.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,3]]}},"alternative-id":["10.1034\/j.1399-3062.2000.020102.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1399-3062.2000.020102.x","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3]]}}}